Most Clicked StoriesMore >


Canada's Ebola vaccine enters human trial in U.S.

BIO SmartBrief | Oct 14, 2014

NewLink Genetics initiated a clinical trial in Silver Spring, Md., to assess the safety and efficacy of an experimental Ebola vaccine in healthy individuals, according to Canada's health minister. The vaccine, licensed to NewLink Genetics, was developed by Canada's health agency. Results are expected to be available in December. Ottawa Citizen (Ontario) (10/12) Reuters (10/13)


AbbVie to reconsider $54B merger with Shire

BIO SmartBrief | Oct 16, 2014

FDA allows Chimerix to conduct trials of experimental Ebola drug

BIO SmartBrief | Oct 17, 2014

BIO criticizes FDA's policy on fixed-dose combo drug exclusivity

BIO SmartBrief | Oct 13, 2014

BIO urges FDA to revise draft biologic exclusivity guidelines

BIO SmartBrief | Oct 16, 2014

Idiopathic pulmonary fibrosis drugs from Roche, Boehringer win FDA approval

BIO SmartBrief | Oct 16, 2014

Pancreatic cancer drug developer applies for FDA orphan status

BIO SmartBrief | Oct 15, 2014

People don't understand biotech foods but still consider them bad, show finds

BIO SmartBrief | Oct 14, 2014

New molecule could hasten search for Ebola drugs

BIO SmartBrief | Oct 15, 2014

Aastrom Biosciences to change name, relocate HQ to Boston area

BIO SmartBrief | Oct 13, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Secure document sharing services optimized for life science organizations

BIO SmartBrief | Oct 20, 2014

Summer 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Oct 17, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Oct 16, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Oct 15, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Oct 14, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more